Moreover, the newly developed HDAC6 inhibitor PB118 demonstrated multiple mechanisms of action, including clearing amyloid-beta deposits, improving the tubulin/microtubule network, regulating inflammation, and reducing phospho-tau levels in AD models. This evidence concerns the gene MAPT and Alzheimer disease.